Medical Marijuana Inc (MJNA)

[Ecostate]

-KANNALIFE -WAY Ahead of the COVID-19 pandemic CBD Patents-( trademark and patent- In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFa, Il-1ß, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”). https://www.kannalife.com/kannalife-inc-receives-notice-of-allowance-from-uspto-for-trademark-of-atopidine/